Dalifard I, Daver A, Goussard J, Lorimier G, Gosse-Brun S, Lortholary A, Larra F
Laboratoire de Radioanalyse, Centre Paul Papin, 49033 Angers Cedex 01, France.
Int J Mol Med. 1998 May;1(5):855-61. doi: 10.3892/ijmm.1.5.855.
In breast cancer, DNA amplification of the oncogene c-erbB-2, encoding for the p185 protein, is associated with a poor prognosis. A retrospective study on a population of 220 cases of primary breast cancer permitted a quantitative measure of p185 oncoprotein overexpression by an immunoenzymetric assay and the determination of c-erbB-2 amplification by the Southern blot method. A correlation existed between the two measurements (r=0.85) using the double cut-off: DNA 2 copies and p185 400 U/mg protein, and only 2.7% of the cases were discordant. 13.2% of the tumors showed p185 overexpression. The percentage of tumors overexpressing p185 was significantly different between the groups with amplified and non-amplified c-erbB-2. We observed a significant correlation between p185 levels and tumor grade (p=0.03), and an inverse correlation with hormonal receptors (p=0.0001). The p185 assay could be an additional prognostic factor to better define patient subgroups with node negative, grade II, and positive or negative hormonal receptors.
在乳腺癌中，编码p185蛋白的癌基因c-erbB-2的DNA扩增与预后不良相关。一项针对220例原发性乳腺癌患者的回顾性研究，通过免疫酶测定法定量检测了p185癌蛋白的过表达情况，并采用Southern印迹法测定了c-erbB-2的扩增情况。使用双临界值（DNA 2拷贝和p185 400 U/mg蛋白）时，这两种检测结果之间存在相关性（r = 0.85），仅有2.7%的病例结果不一致。13.2%的肿瘤显示p185过表达。在c-erbB-2扩增组和未扩增组之间，p185过表达的肿瘤百分比存在显著差异。我们观察到p185水平与肿瘤分级之间存在显著相关性（p = 0.03），与激素受体呈负相关（p = 0.0001）。p185检测可能是一个额外的预后因素，有助于更好地界定具有淋巴结阴性、II级以及激素受体阳性或阴性的患者亚组。
